Those with BRAF-mutant melanoma have the options of anti-PD-1 monotherapy or dabrafenib–trametinib where the choice depends on patients wishes for oral agents versus intravenous therapy, the adverse event profiles, and comorbid conditions. Here, BRAF is linked to melanoma.